WallStSmart

Equinor ASA ADR (EQNR)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Equinor ASA ADR generates 3347% more annual revenue ($105.98B vs $3.07B). WST leads profitability with a 16.1% profit margin vs 4.8%. WST appears more attractively valued with a PEG of 2.89. WST earns a higher WallStSmart Score of 55/100 (C-).

EQNR

Hold

45

out of 100

Grade: D+

Growth: 2.0Profit: 6.5Value: 4.7Quality: 6.5
Piotroski: 3/9Altman Z: 2.32

WST

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 8.0Value: 4.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EQNRSignificantly Overvalued (-116.7%)

Margin of Safety

-116.7%

Fair Value

$13.19

Current Price

$40.46

$27.27 premium

UndervaluedFair: $13.19Overvalued
WSTSignificantly Overvalued (-256.8%)

Margin of Safety

-256.8%

Fair Value

$68.99

Current Price

$247.02

$178.03 premium

UndervaluedFair: $68.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EQNR3 strengths · Avg: 8.3/10
Market CapQuality
$103.74B9/10

Large-cap with strong market position

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
21.4%8/10

Strong operational efficiency at 21.4%

WST2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Areas to Watch

EQNR4 concerns · Avg: 2.5/10
Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.572/10

Expensive relative to growth rate

Revenue GrowthGrowth
-5.1%2/10

Revenue declined 5.1%

WST3 concerns · Avg: 3.3/10
P/E RatioValuation
36.1x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
2.1%4/10

2.1% earnings growth

PEG RatioValuation
2.892/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : EQNR

The strongest argument for EQNR centers on Market Cap, Price/Book, Operating Margin.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.

Bear Case : EQNR

The primary concerns for EQNR are Profit Margin, Piotroski F-Score, PEG Ratio. Thin 4.8% margins leave little buffer for downturns.

Bear Case : WST

The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.

Key Dynamics to Monitor

EQNR profiles as a value stock while WST is a mature play — different risk/reward profiles.

WST carries more volatility with a beta of 1.18 — expect wider price swings.

WST is growing revenue faster at 7.5% — sustainability is the question.

WST generates stronger free cash flow (175M), providing more financial flexibility.

Bottom Line

WST scores higher overall (55/100 vs 45/100), backed by strong 16.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Equinor ASA ADR

ENERGY · OIL & GAS INTEGRATED · USA

Equinor ASA, an energy company, is engaged in the exploration, production, transportation, refining and marketing of petroleum and petroleum products and other forms of energy, as well as other companies in Norway and internationally. The company is headquartered in Stavanger, Norway.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?